Comparisons of different treatments or production processes are the goals of a significant fraction of applied research. Unsurprisingly, two-sample problems play a main role in Statistics through natural questions such as `Is the the new treatment significantly better than the old?'. However, this is only partially answered by some of the usual statistical tools for this task. More importantly, often practitioners are not aware of the real meaning behind these statistical procedures. We analyze these troubles from the point of view of the order between distributions, the stochastic order, showing evidence of the limitations of the usual approaches, paying special attention to the classical comparison of means under the normal model. We discuss the unfeasibility of statistically proving stochastic dominance, but show that it is possible, instead, to gather statistical evidence to conclude that slightly relaxed versions of stochastic dominance hold.
Non-parametric assessment of the calibration of individualized treatment effects
University of British Columbia(不列颠哥伦比亚大学);Amsterdam University Medical Centers(阿姆斯特丹大学医学中心);Smart Data Analysis and Statistics B.V.(智能数据分析与统计有限公司);University Medical Center Göttingen(哥廷根大学医学中心)
Feasible Dose-Response Curves for Continuous Treatments Under Positivity Violations
Ludwig-Maximilians-Universität München(慕尼黑路德维希-马克西米利安大学);Centre for Integrated Data and Epidemiological Research, Cape Town(开普敦综合数据与流行病学研究中心);UMIT – University for Health Sciences, Medical Informatics and Technology(UMIT——健康科学、医学信息和技术大学);Munich Center for Machine Learning (MCML)(慕尼黑机器学习中心)
Reframing Population-Adjusted Indirect Comparisons as a Transportability Problem: An Estimand-Based Perspective and Implications for Health Technology Assessment
A Workflow for Evaluating Regional Treatment Effect Heterogeneity in Multi-Regional Clinical Trials
China Novartis Institutes for BioMedical Research Co.(中国诺华生物医学研究有限公司);Department of Biostatistics, School of Public Health, Peking University(北京大学公共卫生学院生物统计系);Peking University Cancer Hospital(北京大学肿瘤医院);Advanced Methodology and Data Science, Novartis Pharma AG(诺华制药AG高级方法与数据科学部);Advanced Methodology and Data Science, Novartis Pharmaceuticals Corporation(诺华制药公司高级方法与数据科学部);Department of Public Health Sciences, University of Chicago(芝加哥大学公共卫生学系);Biostatistics CRM/NS/IMM, Advanced Quantitative Sciences, Global Drug Development Division, Novartis Pharma K.K.(日本诺华制药K.K.全球药物开发部高级定量科学生物统计CRM/NS/IMM);Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute(北京大学肿瘤医院及研究所癌变与转化教育部重点实验室)
Statistical Design of Pragmatic Trials Using Electronic Health Record Data when Outcome Assessments are Uncontrolled and Irregular
Kaiser Permanente Washington Health Research Institute(凯撒永久华盛顿健康研究所);Kaiser Permanente Center for Health Research Northwest Region(凯撒永久西北区健康研究中心);Department of Biostatistics, School of Public Health, University of Washington(华盛顿大学公共卫生学院生物统计系)